Positive control:
Lane 1: Hela cell lysate
Lane 2: PC-12 cell lysate
Applications
-
WB
-
IHC-P
REACTIVITY
-
Human
-
Mouse
-
Rat
SPECIFICATIONS
Product Type
Recombinant Rabbit monoclonal primary
Product Name
Recombinant NFkB p105/p50 Monoclonal Antibody (ET1603-18)
Immunogen
Synthetic peptide within human nfkb p105/p50 aa 330-370.
Host
Rabbit
Positive Control
Hela cell lysate, PC-12 cell lysate, human tonsil tissue, human spleen tissue, human breast carcinoma tissue, mouse bladder tissue, mouse prostate tissue.
Conjugation
Unconjugated
Clonality
Monoclonal
Clone Number
SZ20-01
PROPERTIES
Form
Liquid
Storage Condition
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
Storage Buffer
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Concentration
1 ug/ul
PURIFICATION
Protein A affinity purified.
MOLECULAR WEIGHT
50/105 kDa
Isotype
IgG
APPLICATION DILUTION
-
WB
-
1:1,000-1:5,000
-
IHC-P
-
1:50-1:200
TARGET
UNIPROT #
PROTEIN NAME
NFkB p105/p50
SYNONYMS
DKFZp686C01211 antibody; DNA binding factor KBF1 antibody; DNA binding factor KBF1 EBP1 antibody; DNA-binding factor KBF1 antibody; EBP 1 antibody; EBP-1 antibody; EBP1 antibody; KBF1 antibody; MGC54151 antibody; NF kappa B antibody; NF kappaB antibody; NF kappabeta antibody; NF kB1 antibody; NFkappaB antibody; NFKB 1 antibody; NFKB p105 antibody; NFKB p50 antibody; Nfkb1 antibody; NFKB1_HUMAN antibody; Nuclear factor kappa B DNA binding subunit antibody; Nuclear factor kappa-B, subunit 1 antibody; Nuclear factor NF kappa B p105 subunit antibody; Nuclear factor NF kappa B p50 subunit antibody; Nuclear factor NF-kappa-B p50 subunit antibody; Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody; p105 antibody; p50 antibody; p84/NF-kappa-B1 p98 antibody; Transcription factor NFKB1 antibody
POST-TRANSLATIONAL MODIFICATION
While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.; Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.; Polyubiquitination seems to allow p105 processing.; S-nitrosylation of Cys-61 affects DNA binding.; The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur as an alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.
SUBCELLULAR LOCATION
Cytoplasm, Nucleus.
FUNCTION
Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor NF B (p50 and p65) and the Drosophila maternal morphagen, dorsal. These proteins share sequence homology over a region of 300 amino acids at their NH2-terminus, the region that contains their DNA binding and dimerization domains. The DNA binding activity of NF B is activated and rapidly transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins have been described. These proteins, designated p105 and p100, are highly related but map on different chromosomes. The p105 (p110) precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated PdI, binds to p50 and regulates its activity.